Natural killer (NK) cells account for approximately 10% to 15% of all circulating lymphocytes 1 and are important early effectors in the innate immune response to a variety of viral infections. 2 Within peripheral blood, NK cells comprise 2 phenotypic and functional subsets 3 : CD56 dim NK cells are considered to be terminally mature and are the primary mediators of contact-dependent lysis of target cells, 1, 3 and CD56 bright NK cells contain less mature NK cell subsets and are potent producers of cytokines. 4, 5 NK cells are derived from CD34 1 precursors, 3, 6 and their development can be stratified to 5 stages 7 characterized by specific surface receptors and proliferative and functional capacities. 8, 9 CD56 bright NK cells are the minor subset (approximately 10%) of NK cells within peripheral blood. 5 They are characterized by low expression of perforin and high expression of CD94-NKG2A receptors, 7 and a subset of cells retain CD117 (c-Kit) expression. 7, 10 NKG2D, NKp46, CD62 ligand, and detectable CD122 are expressed at high levels. [10] [11] [12] [13] [14] These cells are sources of cytokines reflected by high levels of IFN-g and GM-CSF. 1, [7] [8] [9] [10] Functional and phenotypic intermediate populations between CD56 bright and CD56 dim cells have also been described in healthy donors. 9, 11, 15 NK cell terminal maturation is defined by upregulation of perforin, CD16, CD57, CD8, and NKp46 and downregulation of CD94. 7, 11, 13, 14, [16] [17] [18] [19] NK cell development and homeostasis require IL-15, 20, 21 and in both mouse and human systems, NK cells do not develop in the absence of IL-15. 22 Classical natural killer deficiency is characterized by the absence of both NK cells and their cytotoxic function, [23] [24] [25] [26] [27] whereas functional NK cell deficiency is characterized by normal frequencies of NK cells in peripheral blood with decreased function. 28, 29 There are several immune deficiency diseases that affect NK cell development, function, or both. 29 Patients with NK cell deficiency have increased susceptibility to viral infections, including herpesviruses, varicella zoster, herpes simplex, cytomegalovirus, and human papilloma virus. [23] [24] [25] [26] [27] 30 Severe herpesvirus infection with decreased NK cell natural cytotoxicity has been reported in patients with loss-offunction mutations in signal transducer and activator of transcription (STAT) 1 31 and recently in 8 patients with STAT1 gain-of-function (GOF) mutations. 32 The STAT family includes 7 members: STAT1 to STAT4, STAT5a and STATb, and STAT6. 33 Activation through intracellular domains of cytokine receptors, including those for IFN-a/g, IL-2, IL-4, IL-15, IL-21, and IL-6, [34] [35] [36] leads to association with Janus kinase (JAK) family members and recruitment and phosphorylation of STAT proteins. 33, [37] [38] [39] [40] Phosphorylated STAT (pSTAT) proteins form homodimers or heterodimers and translocate to the nucleus, where they bind to consensus sequences in the promoters of target genes. 33, 41 In addition to roles in development and homeostasis, STAT proteins mediate viral defense in NK cells. 42 Upon IL-2 stimulation, pSTAT5 binds 2 enhancers located in the 59 region of the perforin 1 gene (PRF1), promoting its transcription 43 ; upon IL-6 and IL-12 stimulation, this enhancer is bound by pSTAT1 and pSTAT4, respectively. 44, 45 Stat5b knockout mice have significantly lower levels of perforin expression at baseline and greatly decreased NK cell cytolytic function. 46 In human subjects STAT5b deficiency is associated with abnormal NK cell development causing susceptibility to severe viral infections in these patients. 47 Heterozygous GOF mutations in STAT1 lead to significantly higher levels of pSTAT1 and increased STAT1 response to type I and II interferons. 48 These mutations are mostly located in the coiled-coil domain (CCD) or DNA-binding domain (DBD) and lead to an excess of pSTAT1-driven target gene transcription. [48] [49] [50] Patients with these mutations can develop recurrent or persistent chronic mucocutaneous candidiasis (CMC) or other cutaneous mycosis, 48, 49 staphylococcal infections, disseminated dimorphic fungal infections (Coccidioides inmitis and Histoplasma capsulatum), viral infections, and autoimmune disease. [51] [52] [53] [54] Our investigations of patients with unexplained significant viral susceptibility identified functional NK cell defects in patients with STAT1 GOF mutations, suggesting that STAT1 is important for human NK cell differentiation and function. In this study we describe an immature and poorly functioning CD56 dim NK cell population with low perforin expression and impaired cytotoxic capacity in patients with STAT1 GOF mutations. Administration of the specific JAK1/2 inhibitor ruxolitinib, both in vitro and in vivo, restored perforin expression in immature CD56 dim NK cells and partially restored NK cell cytotoxic function. Together, these data demonstrate the effects of ruxolitinib treatment and identify decreased perforin expression and impaired terminal maturation as contributing to functional NK cell defects in patients with STAT1 GOF mutations.
METHODS

Study approval
Blood samples were collected from patients and healthy donors with consent under approved protocols from the Baylor College of Medicine Institutional Review Board and the National Institutes of Health. All samples were collected with sodium heparin collection tubes.
Flow cytometry and antibodies
PBMCs from healthy donors and patients were purified by means of FicollPaque Plus density gradient centrifugation (GE Healthcare, Pittsburgh, Pa). NK cells from all patients with confirmed STAT1 GOF mutations were studied phenotypically by using fluorescence-activated cell sorting and evaluated for NK cell activation, adhesion, inhibitory, and maturation markers, as well as intracellular cytokines and lytic granule content. Intracellular cytokines were evaluated in cells stimulated with phorbol 12-myristate 13-acetate and ionomycin (Sigma-Aldrich, St Louis, Mo) for 6 hours. Brefeldin A (final concentration, 10 mg/mL; Sigma-Aldrich) was added 3 hours before antibody staining. The cells were fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences, San Jose, Calif). Antibodies were purchased from BD Biosciences (CD69, FN50; CD16, B73.1; CD244, 2-69; CD11a, HI111; CD11b, ICRF44; CD18, 6.7; CD94, HP-3D9; perforin, dG9; and CD28, L293), BioLegend (San Diego, Calif; CD56, HCD56; CD3, OKT3; CD16, 3G8; CD8, RPA-T8; NKp46, 9E2; DNAM-1, 11A8; NKG2D, 1D11; CD45, HI30; NKp30, P30-15; CD158b, DX27; CD158d, mAb33; CD62 ligand, DREG-56; CD127, A019D5; CD117, 104D2; CD94, DX22; CD34, 581; GM-CSF, BVD2-1C11; TNF-a, Mab11; IFN-g, 4S.B3; IL-10, JES3-9D7; and IL-13, JES10-5A2), Beckman Coulter (Fullerton, Calif; NKp44, Z231; CD25, B1.49.9; CD2, 39C1.5; CD57, NC1; and CD122, CF1), eBioscience (San Diego, Calif; CD158a, HP-MA4; CD27, O323; and CD107a, eBioH4A3), R&D Systems (Minneapolis, Minn; CD159c, 134591; CD159a, 131411; and CD215, 151303), and Invitrogen (Carlsbad, Calif; Granzyme B, GB11 
Cytotoxicity assays
Antibody-dependent cellular cytotoxicity (ADCC) and NK cell cytotoxicity were measured with the Cr 51 release assay, as previously described. 55 ADCC was evaluated with a Raji cell line incubated in the presence or absence of anti-CD20 (rituximab, 20 mg/mL) and cocultured with fresh PBMCs for 4 hours at 378C in a 5% CO 2 atmosphere. For natural cytotoxicity, PBMCs from patients and healthy donors were incubated for 4 hours with IL-2 (1000 U/mL) and the K562 target cell line. YTS and NK92 cell cytotoxicity was evaluated with K562 cell line by using a 10:1 effector/target ratio. 
STAT activation assays
Proliferation assay
Proliferation was evaluated by using the CellTrace CFSE Cell Proliferation Assay (Life Technologies, Eugene, Ore). PBMCs were stained with 1 mmol/L carboxyfluorescein succinimidyl ester, stimulated with IL-15 (5 ng/mL), and incubated with RPMI-supplemented medium at 378C in a 5% CO 2 atmosphere for 5 days. Cells were then washed and stained with CD3 and CD56 antibodies (BioLegend). Carboxyfluorescein succinimidyl ester intensity was measured by using flow cytometry, and proliferation was evaluated in the CD56 1 CD3 2 population.
Cell lines
The NK92-dependent IL-2 NK cell line is derived from cells of patients with rapidly progressive non-Hodgkin lymphoma. These cells express the following surface markers: CD2, CD7, CD11a, CD28, CD45, and CD54. This cell line does not express the following: CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34, and HLA-DR. 56 NK92 cells were cultured at 378C in Myelocult H5100 medium (STEMCELL Technologies, Vancouver, British Columbia, Canada) supplemented with penicillin/streptomycin (Gibco Life Technologies, Grand Island, NY) and 100 U/mL IL-2 (Cell Signaling).
The NK cell lymphoblastic leukemia (YTS) cell line expressing CD56 
Statistics
The statistical significance of differences between healthy donors and patients was determined by using the unpaired 2-tailed Student t test. Differences between multiple groups were determined by using the ordinary 1-way ANOVA test. Statistical analyses were conducted with Prism 7.0 software (GraphPad Software, La Jolla, Calif).
RESULTS
Patients and clinical manifestations
We evaluated 16 patients with STAT1 GOF disease. The male/female ratio was 1:1, and median age was 18.18 years (range, 3-31 years). Two of these patients died from progressive fungal infections. Clinical features are listed in Table I . Two patients had IgA deficiency (<7 mg/dL). IgG deficiency varied, and 2 patients received IgG replacement. CD4 lymphopenia was present in 3 patients. Eleven patients had less than 0.5% CD4 
IL-17
1 cells (normal range, 0.5% to 2.5%).
STAT1 mutations
Sequencing of STAT1 identified heterozygous mutations in each patient. In 8 patients the mutations were in the CCD, and the remainders were in the DBD (Table I) . Of 8 discrete mutations, 7 have been reported previously 51, 53, 54 ; c.983A>G p.H328R is novel. In vitro STAT1 activation was tested in primary patients' NK cells, representing 5 mutations (3 CCDs and 2 DBDs) in response to IFN-a. We observed persistent phosphorylation without appropriate dephosphorylation in all NK cells from patients when compared with those from healthy donors (Fig 1, A) . Furthermore, mutations in the DBD had significantly greater levels of activated STAT1 after 120 minutes of stimulation than mutations located in the CCD (Fig 1, B) . Interestingly, we observed that patients with mutations in the DBD tend to have a more severe clinical phenotype than patients with CCD mutations (Table I) .
Patients with STAT1 GOF mutations have decreased NK cell cytotoxic function
We performed standard Cr 51 release assays using PBMCs from 14 patients and healthy donor control subjects by using K562 target cells in the presence and absence of exogenous IL-2. We compared the NK cell cytotoxicity activity from each patient with a representative NK cell cytotoxicity from a pool of 10 healthy donors. NK cells from most patients with CCD mutations had residual cytotoxic function that was partially responsive to IL-2 (Fig 2, A , and see Fig E1, A, in this article's Online Repository at www.jacionline.org). In contrast, cells carrying mutations in the DBD had more severe defects in their NK cell cytotoxicity that was not improved by IL-2 (Fig 2, B , and see Fig E1, B) . NK cells from 10 patients were incubated with rituximab-opsonized Raji target cells to assay ADCC. All patients with CCD mutations had residual ADCC (see Fig E2, A, in this article's Online Repository at www.jacionline.org), whereas ADCC in cells from patients with DBD mutations was more impaired (see Fig E2, B) . These data suggest that impairment of NK cell function is affected by the location of the STAT1 mutation.
Impaired terminal maturation of the CD56 dim NK cell subset in patients with STAT1 GOF mutations NK cell-targeted lysis is mediated and enabled by activating and inhibitory receptors on mature NK cells. To determine whether the impaired NK cell cytotoxic function found in our patients was associated with a demonstrable NK cell phenotype, we performed flow cytometry for NK cell developmental markers, functional NK cell receptors (activating and inhibitory), intracellular cytokines, and lytic granule contents. 7 (Fig 3, A) . We observed lower NK cell frequencies in patients with STAT1 GOF mutations (4.0% 6 2.5% [mean 6 SD]) compared with healthy donors (9.7% 6 2.1%). Frequency of the CD56 bright NK cell subset in peripheral blood from patient and control groups was similar. However, patients with STAT1 GOF mutations had a decreased frequency of cells within the CD56 dim NK cell subset (2.631% 6 1.774%) in peripheral blood than healthy donors (9.894%; range, 7.25% to 13.7%; Fig 3, B) , suggesting impaired terminal maturation or survival of the CD56 dim NK cell subset. In healthy donors the CD56 dim NK cell subset is characterized by high levels of expression of CD16 and perforin and acquisition of CD57 and CD8. 7, 16 Patients with STAT1 GOF mutations have abnormal expression with low mean fluorescence intensity of CD16, perforin, CD57, and CD8 (Fig 3, C, (Fig 3, D , and see Fig E3, B) . While the CD56 bright subset in NK cells from patients with STAT1 GOF mutations had higher levels of granzyme B and lower levels of TNF-a (see Fig E3, C) , the CD56 dim subset appears to have impaired terminal maturation. These findings suggest that the CD56 dim subset in patients with STAT1 GOF mutations is immature and potentially nonfunctional.
STAT1 GOF mutations lead to decreased perforin expression and cytotoxic capacity in NK cell lines
To further delineate the effect of STAT1 dysregulation on NK cell phenotype and function, we modeled 2 of the DBD mutations (E353K and T385M) in YTS NK cell lines using CRISPR-Cas9-mediated gene editing. Although expression of total STAT1 was not affected by either mutation in either cell line (data not shown), both mutant cell lines showed enhanced STAT1 phosphorylation in response to IFN-a stimulation compared with wild-type (WT) cells (Fig 4, A) .
To further elucidate the abnormality seen in the primary cells, we looked at select developmental markers in this cell line. Expression of CD94 and NKG2A was increased in mutant cell lines compared with WT (Fig 4, B) . Furthermore, we detected decreased perforin expression of YTS STAT1 mutant cell lines compared with WT (Fig 4, B) .
To determine whether these phenotypic differences corresponded with an effect on function, we performed Cr 51 release cytotoxicity assays and observed that the cytotoxic capacity of YTS STAT1 mutants was decreased more than 4-fold compared with WT values (Fig 4, C) . Similarly, expression of the CCD M202I mutation in a different NK cell line, NK92, led to an analogous functional phenotype (Fig 4, D , and see Fig E4 in this article's Online Repository at www.jacionline.org), with decreased perforin expression and reduced NK cell cytotoxic function (Fig 4, D) . This phenotype was consistent with our results from primary patients' cells because the effect of CCD mutations was milder than that of DBD mutations and defines the impact of patient-derived mutant STAT1 GOF on NK cell perforin expression and maturation signatures.
STAT1 GOF mutations impair STAT5 phosphorylation in NK cells
Functional assays were performed in patients with mutations in CCD (patients 2, 4, 5, 6, 7, and 8) and DBD (patients 11, 15, and 16). Considering the vital STAT-related role of IL-15 in NK cell development and homeostasis, we evaluated the proliferative capacity of NK cells from patients with STAT1 GOF mutations 13, and 15) . B, Levels of STAT1 activated 120 minutes after stimulation. HD, Healthy donor; MFI, mean fluorescence intensity; Pt; patient. Statistical significance was analyzed by using ordinary 1-way ANOVA. ***P < .001 and ****P < .0001.
in response to IL-15 stimulation. All patients tested had significantly decreased proliferation compared with healthy donors independent of the affected domain (Fig 5, A) . Significant crosstalk between STAT signaling molecules exists, including antagonistic binding to common enhancer elements. In particular, the competitive binding of STAT3 and STAT5 to a common 59 perforin enhancer has been demonstrated in T lymphocytes, dendritic cells, and cancer cell lines. 19, 43, 59 On the other hand, STAT5 induces perforin expression in response to IL-2. 43 To determine whether the delayed dephosphorylation of STAT1 affects STAT5 activation and leads to significantly decreased perforin expression in NK cells from patients with STAT1 GOF mutations, we evaluated STAT5 activation after IL-2 stimulation. We observed significantly decreased STAT5 activation in response to IL-2 in CD56 dim NK cells from the CCD and DBD mutations (Fig 5, B) . Interestingly, patients with DBD mutations had lower levels of perforin compared with patients with CCD mutations (Fig 5, C) . Lower levels of pSTAT5 in patients with DBD mutations after 30 minutes of stimulation correspond to the degree of impairment of perforin expression in NK cells from patients with STAT1 GOF mutations (Fig 5,  B and C) .
To determine whether low NK cell proliferation with IL-15 stimulation and low STAT5 activation in response to IL-2 were due to abnormal IL-2 and IL-15 receptor expression, we measured their expression using flow cytometry. We found normal receptor expression for IL-2 and IL-15 in healthy donors and affected subjects (data not shown). Therefore the degree of impairment of NK cell proliferation and perforin expression in NK cells from patients with STAT1 GOF mutations tracks with the degree of impairment in STAT5 activation.
Ruxolitinib treatment restores perforin expression and cytotoxicity in CD56 dim NK cells from patients with STAT1 GOF mutations
Recently, 3 studies reported the efficacy of JAK1/2 pathway inhibition by ruxolitinib in patients with STAT1 GOF mutations. Constitutive hyperphosphorylation of STAT1 in these patients was inhibited, whereas STAT3 phosphorylation was not affected. Importantly, ruxolitinib treatment led to improvement of CMC and autoimmunity. [60] [61] [62] We sought to determine whether ruxolitinib affected the phenotype of NK cells from patients with STAT1 GOF mutations. We evaluated NK cell phenotype and function from 3 patients (patients 3, 9, and 11) before and during oral ruxolitinb treatment. We observed higher levels of CD56 dim Perforin 1 NK cells after treatment with restoration of perforin expression on CD56 dim NK cells during ruxolitinib treatment (Fig 6, A, and see Fig E5, A, in this article's Online Repository at www.jacionline.org) accompanied by an improvement in NK cytotoxicity at baseline with a 2.5-fold increase in NK cytotoxicity in response to IL-2 (Fig 6, B) in patient 9 (from 4% to 9%) and a 2-fold increase in patient 11 (from 3% to 6%). In addition, the ADCC from patient 11 showed a 3-fold increase (from 1% to 3%; see Fig E5, C) . Increased perforin expression accompanied improved NK cytotoxic function. We did not observe an increase in NK cytotoxicity in patient 3, likely because of the short duration of treatment when the assay was performed (see Fig E5, B) . Patients 9 and 11 had been taking ruxolitinib for at least 3 months when the post-ruxolitinib assays were performed, whereas patient 3 was treated for only 2 weeks. Perforin restoration is immediate, although improvement in cytotoxicity comes with a longer duration of therapy. Weinacht et al 62 reported a patient with clinical and laboratory improvement after a year of ruxolitinib treatment. Taking our experiences together, it appears that at least 3 months of therapy with ruxolitinib is needed to demonstrate improvement in function. show mean fluorescence intensity (MFI) for each NK cell receptor expressed by CD56 dim NK cells. Each blue circle represents a healthy donor, and a red box represents a patient with a STAT1 GOF mutation. Horizontal bars represent means, and vertical bars indicate the SD. Statistical significance was analyzed by using the unpaired Student t test. Results are representative of 3 independent experiments. HD, Healthy donor; Pt, patient. **P < .01, ***P < .001, and ****P < .0001. Interestingly, although perforin expression increased, CD16, CD8, and CD57 expression was not affected (see Fig E5, D) . Despite the dramatic increase in perforin expression and improved NK cell cytotoxicity, the course of the fungal infection was so advanced in patient 11 when treatment was started that her disease was not ameliorated, and she eventually died. However, with acyclovir prophylaxis, she did not have any breakthrough herpes infections. Patient 9 experienced significant improvement in his enteropathy and chronic norovirus. His stool output decreased from 3 L of stool per day to 2 to 3 loose stools 4 weeks after treatment began and then 1 to 2 formed stools per day by 3 months after treatment.
To determine whether ruxolitinib had a direct effect on perforin expression, we evaluated STAT5 phosphorylation after stimulation with IL-2 in dim NK cells from patients with CCD or DBD mutations. Statistical significance was analyzed by using ordinary 1-way ANOVA. *P < .05, **P < .01, ***P < .001, and ****P < .0001. HD, Healthy donors; MFI, mean fluorescence intensity. CCD for patients 2, 4, 5, 6, 7, and 8 and DBD for patients 11, 15, and 16. Results are representative of 2 independent experiments for each patient. stimulation (Fig 6, C) , which also corresponds to low perforin expression in pretreatment samples. After ruxolitinib treatment, we observed higher levels of STAT5 activation in posttreatment samples from patients 9 and 11 (Fig 6, D) . These results demonstrate that decreased activation of STAT1 through JAK inhibition affects STAT5 activation and, in turn, perforin expression.
To complement the studies on the in vivo effects of ruxolitinib treatment over perforin expression, we incubated PBMCs isolated cells and perforin expression on the CD56 dim NK cell subset before and after treatment. B, Natural cytotoxicity was performed with the Cr 51 release protocol with freshly isolated PBMCs from patients 9 and 11 and a respective healthy donor and was tested against K562 target cells in the presence or absence of 1000 U/mL IL-2. C and D, STAT5 activation in CD56 dim NK cells after stimulation with IL-2 from patients 3, 9, and 11 (before treatment; Fig 6, C) and in CD56 dim NK cells from patients 9 and 11 (after treatment; Fig 6,  D) . E, PBMCs from patient 13 were incubated in vitro for 48 hours with or without 1 mmol/L ruxolitinib, and perforin expression was measured in CD56 dim NK cells. Statistical significance was analyzed by using ordinary 1-way ANOVA. *P < .05, **P < .01, and ***P < .001. from another patient (patient 13) for 48 hours with 1 mmol/L ruxolitinib. Perforin expression was restored partially in CD56 dim NK cells (Fig 6, E) , whereas perforin levels observed in CD56 dim NK cells from healthy donors were not affected. Similar results were observed by using the STAT1 GOF NK cell line (see Fig E5, E) . Thus inhibition of JAK1/2 signaling in vivo and in vitro leads to normalized STAT1 phosphorylation and partial restoration of NK cell function in NK cells from patients with STAT1 GOF mutations. Although the maturation defect in NK cells from patients with STAT1 GOF mutations is not rescued, direct modulation of STAT1 phosphorylation with ruxolitinib can partially remediate poor NK cell function in these patients.
DISCUSSION
Patients with STAT1 GOF mutations have impaired IL-17A and IL-17F immunity associated with CMC. 48, 49, 53 However, impaired IL-17 immunity does not fully explain the susceptibility to viral infections. 52, 54 STAT1 loss-of-function mutations have been reported with impaired NK cell activity and cytomegalovirus infection. 31 Association of herpesvirus infection with NK cell deficiency led us to investigate the phenotype and function of NK cells in patients with STAT1 GOF mutations. We identified that excess STAT1 phosphorylation caused by these mutations is associated with impaired NK cell terminal maturation, decreased expression of the critical cytolytic effector molecule perforin, and impaired cytolytic function. Importantly, these effects can be ameliorated partially in vivo and in vitro by treatment with the JAK1/2 inhibitor ruxolitinib.
We found that the STAT1 GOF mutation-associated CD56 dim NK cell subset has an immature phenotype characterized by aberrant expression of CD94, CD117, and NKG2A, molecules associated with the CD56 bright subset, as well as low levels of CD16, perforin, CD57, and CD8. Although a similar developmentally intermediate population typically makes up between 20% and 40% of CD56 dim NK cells in healthy donors, 11, 15, 63 it comprised the majority (80%) of CD56 dim NK cells found within the peripheral blood of patients with STAT1 GOF mutations. Notably, The STAT1 GOF CD56 dim population is characterized by low levels of CD16 and perforin, 2 important components of the cytotoxic capacity to eliminate infected cells.
Interestingly, DBD mutations generally conferred a more profound NK cell defect than those in the CCD. The mutated STAT1 domain is important in the severity of NK cell dysfunction in patients with STAT1 GOF mutations. However, expression of both CCD and DBD mutations in NK cell lines had an equal effect on perforin expression and cytotoxic capacity, suggesting that additional factors might dictate the effect of the STAT1 mutation on NK cell function. This variability in phenotype has also recently been reported by Tabellini et al, 32 who describe a cohort of patients with STAT1 GOF mutations with normal perforin and CD16 expression.
STAT5 phosphorylation and signaling, including IL-15-mediated proliferation, are impaired in patients with STAT1 GOF mutations. STAT5's unique role in NK cell proliferation and cytotoxic activity suggests that its impairment can cause at least some of the NK cell maturation defect seen in patients with STAT1 GOF mutations. 19, 46 In addition, binding of STAT5 to the 59 enhancer in the PRF gene likely contributes specifically to the downregulation of perforin in patients' NK cells. Re-expression of perforin upon reduction of STAT1 phosphorylation suggests that this is not a hardwired developmental defect. The mechanism of suppression of STAT5 by excess STAT1 phosphorylation is unclear. STAT1-induced suppressor of cytokine signaling (SOCS)-mediated negative regulation of STAT5 is one possibility, and the recent description of increased SOCS1 and SOCS3 expression in NK cells from patients with STAT1 GOF mutations supports this hypothesis. 32 The lack of rescue of overexpression of CD94/NKG2A and CD117 on CD56 dim NK cells after ruxolitinib treatment suggests that these markers are not directly modulated by excess STAT1 signaling.
With the onset of genetic testing in patients with primary immunodeficiency disease, we can now choose therapies that modulate a specific target. 64 For example, abatacept is now successfully used to treat cytotoxic T lymphocyte-associated antigen 4 haploinsufficiency, as well as other directed cytokine and biologic therapies for a wide range of primary immunodeficiency diseases. 65 Autoimmune disease in patients with STAT3 GOF disease was successfully treated with IL-6 receptor blockade. 66 Treatment with the JAK1/2 inhibitor ruxolitinib in a patient with refractory candida esophagitis led to resolution of many symptoms within a 5-month period. 60 Increases in IL-17 production in patients with STAT1 GOF mutations after treatment with ruxolitinib was also associated with reduced burden of CMC, reduced hyperresponsiveness to type I and II interferons, normalized T H 1 and follicular T H responses and had remission of the autoimmune-mediated cytopenias. 61, 62 Our results demonstrate that perforin expression and NK cell cytotoxic capacity are partially restored after in vivo treatment, suggesting that ruxolitinib can improve NK cell function, but its effect on other lymphoid and myeloid elements must be assessed to determine the therapeutic utility of ruxolitinib in patients with STAT1 GOF disease.
In conclusion, STAT1 GOF mutations cause a distinct NK cell phenotype, likely because of impairment in NK cell terminal maturation. These mutations cause poor perforin expression, and this NK cell population has decreased or absent NK cell cytotoxic activity. Importantly, perforin expression and NK cell function are restored in part by JAK inhibition with ruxolitinib. These data indicate that STAT1 has critical roles in NK cell development and maturation through direct mediation of cytotoxic mediators and through modulation of other mediators, including STAT5. (Fig E3, B) or CD56 bright (Fig E3, C) NK cells for each receptor. Each blue circle represents a healthy donor (HD), and a red box represents a patient (Pt) with a STAT1 GOF mutation. Horizontal bars represent means, and vertical bars indicate SDs. Statistical significance was analyzed by using the unpaired Student t test. Results are representative of 3 independent experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
